Table 2.
Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in intravenous immunoglobulin (IVIG) responding or non-responding patients with Kawasaki disease
| Characteristic | IVIG responders (n = 36) | IVIG non-responders (n = 4) | P | |
|---|---|---|---|---|
| Boys/girls, number | 21/15 | 1/3 | 0.000 | |
| Age, months | 22.4 (17.2) | 30.5 (12.8) | 0.000 | |
| Patients with CALs, number | 7 | 2 | 0.000 | |
| Resistin, 102 ng/ml | Acute stage | 0.35 (0.24) | 0.64 (0.30) | 0.032 |
| Afebrile stage | 0.21 (0.19) ** | 0.48 (0.35) | 0.019 | |
| Subacute stage | 0.12 (0.05) **▲ | 0.28 (0.19) | 0.000 | |
| S100A12, 102 ng/ml | Acute stage | 5.05 (3.22) | 7.92 (2.61) | 0.044 |
| Afebrile stage | 3.99 (3.49) | 4.80 (4.26) | 0.668 | |
| Subacute stage | 2.35 (2.26)** ▲ | 4.98 (4.75) | 0.047 | |
| sRAGE, 102 pg/ml | Acute stage | 3.07 (1.98) | 2.37 (0.96) | 0.493 |
| Afebrile stage | 6.00 (2.78)** | 3.51 (2.64) | 0.046 | |
| Subacute stage | 7.19 (2.88)** | 3.65 (3.27) | 0.026 | |
Results are mean (SD) unless stated otherwise. CALs, coronary artery lesions; **P < 0.01 compared with acute stage; ▲P < 0.05 compared with afebrile stage.